Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder

Eric Hollander, Latha Soorya, Stacey Wasserman, Katherine Esposito, William Chaplin, Evdokia Anagnostou

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Autism is a neurodevelopmental disorder characterized by impairment in three core symptom domains: socialization, communication, and repetitive/stereotyped behaviours. Other associated symptom domains are also affected including impulsivity/aggression, self-injury, anxiety, and mood lability. Divalproex has been shown to have efficacy in treating epilepsy, bipolar disorder, mood lability, and impulsive aggression. The present study evaluated the use of divalproex in the treatment of repetitive, compulsive-like symptoms of autism spectrum disorder (ASD). Thirteen individuals with ASD participated in an 8-wk, double-blind, placebo-controlled trial of divalproex sodium vs. placebo. There was a significant group difference on improvement in repetitive behaviours as measured by the Children's Yale-Brown Obsessive Compulsive Scale (C-YBOCS) (p = 0.037) and a large effect size (d = 1.616). This study provides preliminary support for the use of divalproex in treating repetitive behaviours in ASD. Further research is needed to evaluate the specificity and mechanism of action of these findings.

Original languageEnglish (US)
Pages (from-to)209-213
Number of pages5
JournalInternational Journal of Neuropsychopharmacology
Volume9
Issue number2
DOIs
StatePublished - Apr 2006
Externally publishedYes

Fingerprint

Valproic Acid
Placebos
Aggression
Stereotyped Behavior
Socialization
Impulsive Behavior
Therapeutics
Autistic Disorder
Bipolar Disorder
Epilepsy
Anxiety
Communication
Autism Spectrum Disorder
Wounds and Injuries
Research

Keywords

  • Autism
  • Divalproex
  • Repetitive behaviours
  • Valproate

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Neuropsychology and Physiological Psychology
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. / Hollander, Eric; Soorya, Latha; Wasserman, Stacey; Esposito, Katherine; Chaplin, William; Anagnostou, Evdokia.

In: International Journal of Neuropsychopharmacology, Vol. 9, No. 2, 04.2006, p. 209-213.

Research output: Contribution to journalArticle

Hollander, Eric ; Soorya, Latha ; Wasserman, Stacey ; Esposito, Katherine ; Chaplin, William ; Anagnostou, Evdokia. / Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. In: International Journal of Neuropsychopharmacology. 2006 ; Vol. 9, No. 2. pp. 209-213.
@article{28cc10579cc74960860b457703301fb6,
title = "Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder",
abstract = "Autism is a neurodevelopmental disorder characterized by impairment in three core symptom domains: socialization, communication, and repetitive/stereotyped behaviours. Other associated symptom domains are also affected including impulsivity/aggression, self-injury, anxiety, and mood lability. Divalproex has been shown to have efficacy in treating epilepsy, bipolar disorder, mood lability, and impulsive aggression. The present study evaluated the use of divalproex in the treatment of repetitive, compulsive-like symptoms of autism spectrum disorder (ASD). Thirteen individuals with ASD participated in an 8-wk, double-blind, placebo-controlled trial of divalproex sodium vs. placebo. There was a significant group difference on improvement in repetitive behaviours as measured by the Children's Yale-Brown Obsessive Compulsive Scale (C-YBOCS) (p = 0.037) and a large effect size (d = 1.616). This study provides preliminary support for the use of divalproex in treating repetitive behaviours in ASD. Further research is needed to evaluate the specificity and mechanism of action of these findings.",
keywords = "Autism, Divalproex, Repetitive behaviours, Valproate",
author = "Eric Hollander and Latha Soorya and Stacey Wasserman and Katherine Esposito and William Chaplin and Evdokia Anagnostou",
year = "2006",
month = "4",
doi = "10.1017/S1461145705005791",
language = "English (US)",
volume = "9",
pages = "209--213",
journal = "International Journal of Neuropsychopharmacology",
issn = "1461-1457",
publisher = "Cambridge University Press",
number = "2",

}

TY - JOUR

T1 - Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder

AU - Hollander, Eric

AU - Soorya, Latha

AU - Wasserman, Stacey

AU - Esposito, Katherine

AU - Chaplin, William

AU - Anagnostou, Evdokia

PY - 2006/4

Y1 - 2006/4

N2 - Autism is a neurodevelopmental disorder characterized by impairment in three core symptom domains: socialization, communication, and repetitive/stereotyped behaviours. Other associated symptom domains are also affected including impulsivity/aggression, self-injury, anxiety, and mood lability. Divalproex has been shown to have efficacy in treating epilepsy, bipolar disorder, mood lability, and impulsive aggression. The present study evaluated the use of divalproex in the treatment of repetitive, compulsive-like symptoms of autism spectrum disorder (ASD). Thirteen individuals with ASD participated in an 8-wk, double-blind, placebo-controlled trial of divalproex sodium vs. placebo. There was a significant group difference on improvement in repetitive behaviours as measured by the Children's Yale-Brown Obsessive Compulsive Scale (C-YBOCS) (p = 0.037) and a large effect size (d = 1.616). This study provides preliminary support for the use of divalproex in treating repetitive behaviours in ASD. Further research is needed to evaluate the specificity and mechanism of action of these findings.

AB - Autism is a neurodevelopmental disorder characterized by impairment in three core symptom domains: socialization, communication, and repetitive/stereotyped behaviours. Other associated symptom domains are also affected including impulsivity/aggression, self-injury, anxiety, and mood lability. Divalproex has been shown to have efficacy in treating epilepsy, bipolar disorder, mood lability, and impulsive aggression. The present study evaluated the use of divalproex in the treatment of repetitive, compulsive-like symptoms of autism spectrum disorder (ASD). Thirteen individuals with ASD participated in an 8-wk, double-blind, placebo-controlled trial of divalproex sodium vs. placebo. There was a significant group difference on improvement in repetitive behaviours as measured by the Children's Yale-Brown Obsessive Compulsive Scale (C-YBOCS) (p = 0.037) and a large effect size (d = 1.616). This study provides preliminary support for the use of divalproex in treating repetitive behaviours in ASD. Further research is needed to evaluate the specificity and mechanism of action of these findings.

KW - Autism

KW - Divalproex

KW - Repetitive behaviours

KW - Valproate

UR - http://www.scopus.com/inward/record.url?scp=32844464646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32844464646&partnerID=8YFLogxK

U2 - 10.1017/S1461145705005791

DO - 10.1017/S1461145705005791

M3 - Article

VL - 9

SP - 209

EP - 213

JO - International Journal of Neuropsychopharmacology

JF - International Journal of Neuropsychopharmacology

SN - 1461-1457

IS - 2

ER -